Abstract
Background: Several studies have shown that religiosity has beneficial effects on health, mortality and pathological conditions; little is known about religiosity in Alzheimers disease and the progression of its cognitive, behavioral and functional symptoms. Our aim was to identify any relationship between religiosity and the progression of cognitive impairment and behavioral disorders in mild-moderate Alzheimers disease, and any relationship between the patients religiosity and the stress in caregivers. Materials and Methods: 64 patients with Alzheimers disease were analyzed at baseline and 12 months later using the Mini-Mental State Examination (MMSE), the Behavioral Religiosity Scale (BRS) and the Francis Short Scale (FSS). Caregivers were also questioned on the patients functional abilities (ADL, IADL), the behavioral disturbances (NPI), and on their stress (NPI-D, CBI). Patients were divided into 2 groups according to BRS: a score of < 24 meant no or low religiosity (LR), while a score of ≥24 meant moderate or high religiosity (HR). Findings: LR patients had worsened more markedly after 12 months in their total cognitive and behavioral test scores. Stress was also significantly higher in the caregivers of the LR group. Global BRS and FSS scores correlated significantly with variations after 1 year in the MMSE (r: 0.50), NPI (r:-0.51), NPI-D (r:-0.55) and CBI (r:-0.62). A low religiosity coincided with a higher risk of cognitive impairment, considered as a 3-point decrease in MMSE score (OR 6.7, CI: 1.8- 24.7). Interpretation: Higher levels of religiosity in Alzheimers dementia seem to correlate with a slower cognitive and behavioral decline, with a corresponding significant reduction of the caregivers burden.
Keywords: Religion, Alzheimer disease, Cognitive functions, Behavioral disturbs, Caregiver
Current Alzheimer Research
Title: Does Religiosity Protect Against Cognitive and Behavioral Decline in Alzheimers Dementia?
Volume: 7 Issue: 5
Author(s): A. Coin, E. Perissinotto, M. Najjar, A. Girardi, E.M. Inelmen, G. Enzi, E. Manzato and G. Sergi
Affiliation:
Keywords: Religion, Alzheimer disease, Cognitive functions, Behavioral disturbs, Caregiver
Abstract: Background: Several studies have shown that religiosity has beneficial effects on health, mortality and pathological conditions; little is known about religiosity in Alzheimers disease and the progression of its cognitive, behavioral and functional symptoms. Our aim was to identify any relationship between religiosity and the progression of cognitive impairment and behavioral disorders in mild-moderate Alzheimers disease, and any relationship between the patients religiosity and the stress in caregivers. Materials and Methods: 64 patients with Alzheimers disease were analyzed at baseline and 12 months later using the Mini-Mental State Examination (MMSE), the Behavioral Religiosity Scale (BRS) and the Francis Short Scale (FSS). Caregivers were also questioned on the patients functional abilities (ADL, IADL), the behavioral disturbances (NPI), and on their stress (NPI-D, CBI). Patients were divided into 2 groups according to BRS: a score of < 24 meant no or low religiosity (LR), while a score of ≥24 meant moderate or high religiosity (HR). Findings: LR patients had worsened more markedly after 12 months in their total cognitive and behavioral test scores. Stress was also significantly higher in the caregivers of the LR group. Global BRS and FSS scores correlated significantly with variations after 1 year in the MMSE (r: 0.50), NPI (r:-0.51), NPI-D (r:-0.55) and CBI (r:-0.62). A low religiosity coincided with a higher risk of cognitive impairment, considered as a 3-point decrease in MMSE score (OR 6.7, CI: 1.8- 24.7). Interpretation: Higher levels of religiosity in Alzheimers dementia seem to correlate with a slower cognitive and behavioral decline, with a corresponding significant reduction of the caregivers burden.
Export Options
About this article
Cite this article as:
Coin A., Perissinotto E., Najjar M., Girardi A., Inelmen E.M., Enzi G., Manzato E. and Sergi G., Does Religiosity Protect Against Cognitive and Behavioral Decline in Alzheimers Dementia?, Current Alzheimer Research 2010; 7 (5) . https://dx.doi.org/10.2174/156720510791383886
DOI https://dx.doi.org/10.2174/156720510791383886 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Efficacy of Cognitive Intervention Programs for Mild Cognitive Impairment: A Systematic Review
Current Alzheimer Research Apolipoprotein E Gene Revisited: Contribution of Rare Variants to Alzheimer’s Disease Susceptibility in Southern Chinese
Current Alzheimer Research Protective Effect of Aspirin Against Oligomeric Aβ42 Induced Mitochondrial Alterations and Neurotoxicity in Differentiated EC P19 Neuronal Cells
Current Alzheimer Research Pleiotropic Effects of the Rho-kinase Inhibitor Fasudil After Subarachnoid Hemorrhage: A Review of Preclinical and Clinical Studies
Current Vascular Pharmacology The Cell Cycle and Hormonal Fluxes in Alzheimer Disease: A Novel Therapeutic Target
Current Pharmaceutical Design Alcohol Abuse and HIV Infection: Role of DRD2
Current HIV Research Magnetic Resonance Imaging in Alzheimer’s Disease: from Diagnosis to Monitoring Treatment Effect
Current Alzheimer Research Recent Advances in Nanotechnology-Based Drug Delivery Approaches for Alzheimer disease
Current Drug Targets Clinical and Environmental Correlates of Serum BDNF: A Descriptive Study with Plausible Implications for AD Research
Current Alzheimer Research Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin
CNS & Neurological Disorders - Drug Targets Whole body vibration training improves walking performance of stroke patients with knee hyperextension: a randomized controlled pilot study
CNS & Neurological Disorders - Drug Targets A Systems Biology Consideration of the Vasculopathy of Sickle Cell Anemia: The Need for Multi-Modality Chemo-Prophylaxis
Cardiovascular & Hematological Disorders-Drug Targets Linking Alzheimer’s Disease and Type 2 Diabetes Mellitus via Aberrant Insulin Signaling and Inflammation
CNS & Neurological Disorders - Drug Targets Receptor for AGEs (RAGE) as Mediator of NF-kB Pathway Activation in Neuroinflammation and Oxidative Stress
CNS & Neurological Disorders - Drug Targets Vitamin E and All-Cause Mortality: A Meta-Analysis
Current Aging Science Amyloid-Degrading Enzymes as Therapeutic Targets in Alzheimers Disease
Current Alzheimer Research PET with Non-Standard Nuclides
Current Topics in Medicinal Chemistry Protein Tyrosine Nitration: Role in Aging
Current Aging Science Metabolic Aspects of Prion Diseases: An Overview
Current Drug Targets Editorial (Thematic Issue: Medication Management for People with Dementia or Cognitive Impairment)
Current Clinical Pharmacology